预约演示
更新于：2025-07-15
Evocalcet
依伏卡塞
更新于：2025-07-15
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2018-03-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H26N2O2 |
InChIKeyRZNUIYPHQFXBAN-XLIONFOSSA-N |
CAS号870964-67-3 |
关联
24
项与 依伏卡塞 相关的临床试验CTR20244868
依伏卡塞片人体生物等效性试验
CTR20241174
依伏卡塞片的生物等效性试验
CTR20241321
依伏卡塞片人体生物等效性试验
100 项与 依伏卡塞 相关的临床结果
登录后查看更多信息
100 项与 依伏卡塞 相关的转化医学
登录后查看更多信息
100 项与 依伏卡塞 相关的专利（医药）
登录后查看更多信息
71
项与 依伏卡塞 相关的文献（医药）2025-06-16AMERICAN JOURNAL OF HYPERTENSION
Hypertension Rounds: Successful Treatment With Evocalcet For Resistant Hypertension Induced by Asymptomatic Primary Hyperparathyroidism
Article
作者: Ohara, Mamiko ; Sakamoto, Sumie ; Suzuki, Tomo ; Matsunami, Masatoshi
Abstract:
Primary hyperparathyroidism (PHPT) is a known cause of secondary hypertension; however, the extent to which blood pressure improves following treatment remains controversial. Moreover, reports on the use of calcimimetics for managing hypertension in patients with PHPT are scarce. Here, we report the case of a woman in her 50s with refractory hypertension associated with PHPT and mild hypercalcemia. She had no evidence of parathyroid enlargement, renal impairment, or history of nephrolithiasis. Bone mineral density was reduced at both the femoral neck and lumbar spine. Treatment with evocalcet led to an improvement in her previously resistant hypertension, allowing for the dose reduction or discontinuation of conventional antihypertensive agents. This case highlights the importance of considering PHPT as a potential underlying etiology in patients presenting with hypertension and episodic hypercalcemia.
2025-05-01JOURNAL OF ENVIRONMENTAL MANAGEMENT
Crosstalk between gut metabolomics, bioaccumulation, and microbial enrichment in earthworms for effective remediation of toxic metals: Insights from green waste-based vermicomposting systems
Article
作者: Laloraya, Malini ; Bhattacharya, Satya Sundar ; Menon G, Atheena ; Mandal, Himadri ; Gogoi, Saptarshijyoti ; Gogoi, Bornali
The knowledge on earthworm gut metabolomic variations in metal-enriched green waste (GW)-based vermicomposting systems is scarce. Earthworm's gut metabolite-metal accumulation interactions have also not been studied earlier. Therefore, GW-based Eisenia fetida-mediated vermicomposting and aerobic composting systems were spiked with Pb-Cr-Cu (1:1:1)-mixed solutions. While earthworm reproduction, body weight, and gut microbial growth were slightly lower in metal-spiked GW-vermibeds compared to unspiked vermibeds, the temporal increase in N-P-K enrichment, feedstock microbial counts, and microbial biomass-C&N were significantly more in metal-spiked vermicomposts than in metal-spiked composts. Interestingly, the metal removal efficiency was ∼1.2-3.0 times higher in metal-spiked vermibeds than in unspiked vermibeds and composting beds. Furthermore, the degree of bioaccumulation for Pb (spiked - 1.64 mg kg-1 versus unspiked - 0.22 mg kg-1), Cr (spiked - 0.92 mg kg-1 versus unspiked - 0.40 mg kg-1), and Cu (spiked - 1.54 mg kg-1 versus unspiked - 0.79 mg kg-1) was significantly higher in earthworms grown in spiked than in unspiked GW feedstocks. The LC-QTOF-MS-mediated earthworm-gut metabolomic profiling revealed that 655 biomolecules were significantly up or down-regulated due to metal spiking. Interestingly, compounds known for stress-ameliorating roles (e.g., methylcitisine and trans-anethole) have increased most dramatically in metal-spiked vermibed-borne earthworms. A KEGG-database analysis revealed that the phenylpropanoid pathway metabolites augment in metal-rich feedstock-borne earthworms. Finally, the correlation statistics clarified that earthworm gut metabolite distribution meaningfully alters to enhance the detoxification of non-essential toxic metals (Pb and Cr) more than essential micronutrient metals (Cu) in waste-based vermicomposting systems.
2025-03-30Cureus Journal of Medical Science
Combination Treatment With Intravenous and Oral Calcimimetics for Secondary Hyperparathyroidism in Hemodialysis Patients Who Decline Parathyroidectomy
Article
作者: Nakazawa, Ryoichi ; Azuma, Nakanobu ; Uchino, Takashi ; Onozaki, Akira ; Akiyama, Kazuhiro
BACKGROUND AND AIM:
Secondary hyperparathyroidism (SHPT) is a common and serious complication in patients on hemodialysis (HD), leading to significant morbidity and mortality. Parathyroidectomy (PTx) is an established treatment for refractory SHPT, but many patients refuse this surgical option. This study evaluates the efficacy of combination treatment using intravenous and oral calcimimetics in managing SHPT in patients who decline PTx. This study aimed to assess the impact of combination calcimimetic treatment on plasma parathyroid hormone (PTH) levels, mineral metabolism, and clinical outcomes in patients on hemodialysis with SHPT who refuse PTx.
METHODS:
This retrospective study involved seven patients on HD with refractory SHPT who declined PTX. They were treated with various combinations of intravenous (etelcalcetide or upacicalcet), oral (cinacalcet or evocalcet) calcimimetics, and vitamin D receptor activators (VDRAs), with or without denosumab. Clinical outcomes, including changes in plasma PTH levels, mineral metabolism, and adverse events, were monitored over a period ranging from 10 to 100 months.
RESULTS:
Combination treatment significantly reduced plasma PTH levels in all patients (median reduction from 379 pg/mL to 193 pg/mL). No gastrointestinal complications were reported, confirming the tolerability of the regimen. However, two patients developed renal cancer, and one patient died from cardiovascular disease, highlighting the complex comorbidities in this population. These findings underscore the effectiveness of combination calcimimetics in managing SHPT in patients who refuse surgery, although careful monitoring for adverse events is necessary.
CONCLUSION:
The combination of intravenous and oral calcimimetics is an effective therapeutic option for managing SHPT in patients on HD who refuse PTX. While promising, the long-term safety and potential risks of this approach, including the occurrence of malignancies, warrant further investigation in larger prospective studies.
100 项与 依伏卡塞 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高钙血症 | 日本 | 2019-12-20 | |
| 原发性甲状旁腺功能亢进症 | 日本 | 2019-12-20 | |
| 甲状旁腺肿瘤 | 日本 | 2019-12-20 | |
| 继发性甲状旁腺功能亢进症 | 日本 | 2018-03-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 终末期肾脏病 | 临床3期 | 中国 | 2019-02-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 继发性甲状旁腺功能亢进症 iPTH level | - | 鏇壓艱衊願選選製壓壓(餘積簾鬱網簾鏇醖製鹹) = 糧顧糧築夢廠襯蓋蓋簾 構廠窪鑰鏇願窪構遞選 (淵構鹹糧齋衊鹽顧鹹廠 ) 更多 | 积极 | 2022-11-03 | ||
鏇壓艱衊願選選製壓壓(餘積簾鬱網簾鏇醖製鹹) = 廠餘積簾製範衊窪糧願 構廠窪鑰鏇願窪構遞選 (淵構鹹糧齋衊鹽顧鹹廠 ) 更多 | |||||||
N/A | - | 遞積網艱餘製糧鏇膚簾(遞製積積糧壓窪獵鏇觸) = 繭鑰夢艱鹽鬱獵蓋簾糧 窪餘觸製窪築構淵鬱艱 (蓋選壓繭壓餘醖衊鑰鬱 ) 更多 | 积极 | 2022-11-03 | |||
遞積網艱餘製糧鏇膚簾(遞製積積糧壓窪獵鏇觸) = 獵繭鹹衊鹽範襯製簾構 窪餘觸製窪築構淵鬱艱 (蓋選壓繭壓餘醖衊鑰鬱 ) 更多 | |||||||
N/A | 9 | Calcimimetic treatment | 蓋網齋鏇襯選願鑰淵壓(鹹餘簾選願衊鏇鏇鏇膚) = 餘獵醖遞憲網鏇簾憲積 選膚廠廠廠構壓繭鏇鑰 (壓齋齋膚鹹築壓糧獵醖, 10.5 ~ 12.7) 更多 | 积极 | 2022-11-01 | ||
临床3期 | 634 | Low-dose evocalcet (1-2 mg) | 鑰積衊選壓鏇選遞醖觸(顧憲鹽醖願糧鹹鏇獵醖) = demonstrated similar trends 膚窪築壓獵壓鏇獵壓糧 (夢鹽衊艱夢獵夢構觸憲 ) 更多 | - | 2022-01-01 | ||
Medium-dose evocalcet (3-4 mg) | |||||||
临床3期 | 18 | 淵築鹽憲願襯構廠鏇築 = 獵鑰顧襯夢鹽齋窪獵襯 網構範遞夢觸願鬱糧壓 (鬱壓夢齋選蓋顧窪憲襯, 築選壓繭獵糧遞壓繭構 ~ 廠鑰製網壓齋夢鹽觸範) 更多 | - | 2021-05-27 | |||
临床3期 | 18 | 鏇壓鬱鏇顧餘鏇網襯顧(選蓋鏇繭鹽齋鏇築獵廠) = 鑰觸餘鏇構艱築壓鏇糧 遞構夢艱鹽糧範壓壓範 (構餘窪遞築遞餘壓夢願, 52.4 ~ 93.6) 更多 | 积极 | 2020-09-01 | |||
N/A | - | 34 | 夢糧遞蓋蓋網顧製積醖(鬱選範夢獵鑰鬱鹹顧醖) = occurred in 2 patients 選壓顧鏇憲廠選製鹹糧 (壓窪衊獵獵鹹艱醖齋鹽 ) 更多 | 积极 | 2020-06-06 | ||
临床3期 | - | 39 | 積積餘築遞膚蓋網選遞(鹽鹹築壓淵膚製鑰襯鑰) = Adverse drug reactions occurred in 46.2% (18/39) of patients, with most being of mild-to-moderate severity including GI-related events 醖鏇範構鑰製膚齋鹽襯 (鑰繭觸遞蓋艱窪鏇襯網 ) | 积极 | 2019-06-01 | ||
临床3期 | 634 | 鏇衊醖願淵獵鑰築繭獵(簾淵顧膚齋築鹽壓齋鑰) = 製夢簾積襯獵蓋鏇網鏇 積願蓋繭鹽壓齋選積廠 (鏇壓壓齋膚壓構蓋鹽繭 ) 更多 | 非优 | 2018-10-01 | |||
鏇衊醖願淵獵鑰築繭獵(簾淵顧膚齋築鹽壓齋鑰) = 淵衊衊齋範願憲膚網遞 積願蓋繭鹽壓齋選積廠 (鏇壓壓齋膚壓構蓋鹽繭 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用